The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Oral cryotherapy, Routine oral care.
- Who it may be relevant to
- Registry conditions: Advanced or Metastatic Breast Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer: A Randomized, Controlled, Multicenter Clinical Study
Overview
The incidence of oral mucositis associated with TROP2-ADC therapy in patients with advanced breast cancer is notably high. Identifying effective preventive and therapeutic strategies is essential for enhancing patient quality of life and optimizing treatment outcomes. Oral cryotherapy has been demonstrated to be efficacious in mitigating oral mucositis induced by radiotherapy and chemotherapy. Consequently, this study seeks to investigate the potential preventive efficacy of oral cryotherapy on TROP2-ADC-induced oral mucositis in patients with advanced breast cancer
Interventions
- Other Oral cryotherapy
Patients randomly assigned to the experimental group underwent TROP2-ADC treatment. They continuously held ice cubes and ice water from 15 minutes before the infusion, throughout the infusion process, and for 15 minutes after the infusion. Ice cubes were promptly replaced with fresh ones as they melted. Patients were instructed not to consume any food or liquids orally for 1 hour following the completion of the ice therapy. - Other Routine oral care
Patients in the control group did not receive oral cryotherapy during the TROP2-ADC infusion but only received routine oral care.
Primary outcome measures
- The incidence and severity of oral mucositis within 8 weeks (scored according to the CECAE 5.0 standard) [Time frame: From the start of TROP2-ADC treatment to the 8th week]
Secondary outcome measures (3)
- The incidence and severity of oral mucositis at week 12 and week 24 [Time frame: From the start of TROP2-ADC treatment to the 12th and 24th week]
- Progression-free survival(PFS) [Time frame: Up to approximately 28 weeks]
- Treatment interruption rate [Time frame: Up to approximately 28 weeks]
Eligibility criteria
Inclusion criteria
- Participants voluntarily enrolled in the study, signed the informed consent form, and demonstrated good compliance.
- Age ≥ 18 years at the time of informed consent signing.
- Patients with locally advanced or recurrent/metastatic breast cancer receiving TROP2-ADC treatment for the first time.
- ECOG PS: 0-2 points;
- The expected survival time was more than 3 months;
- Adequate organ and bone marrow function, with no transfusions or treatments with recombinant human thrombopoietin or colony-stimulating factors within 1 week before the first dose, is defined as follows:
- Blood routine: Neutrophil count (NEUT#) ≥ 1.5×109/L; Platelet (PLT) ≥ 75×109/L; Hemoglobin ≥ 90g/L
- Liver function: AST and ALT ≤ 3 × ULN; for patients with liver metastasis, AST and ALT ≤ 5 × ULN.
- Renal function: Creatinine ≤ 1.5 × ULN or Ccr ≥ 60 ml/min (Cockcroft-Gault formula provided).
- Cardiac function: LVEF ≥ 50% by ECHO or MUGA scan.
- Patients with a negative pregnancy test and reproductive potential must agree to use effective non-hormonal contraception during treatment and for at least 3 months after the last dose of the investigational drug.
- Voluntary participants who sign informed consent, demonstrate good compliance, and agree to follow-up.
Exclusion criteria
- Prior TROP2-targeted treatment was administered.
- Patients with active oral mucositis or oral ulcers were excluded.
- Patients with serious concomitant diseases, as judged by researchers, that threaten safety or impede study completion, including uncontrolled hypertension, severe diabetes, and active infections, were excluded.
- Other conditions where the investigator determines the patient is unsuitable for study participation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
China · 1 center
- Henan Cancer Hospital — Zhengzhou
Identifiers
NCT: NCT06934733 · HNCH-MBC17